Most skin cancers are not fatal. The vast majority are caught early, treated successfully, and never come back. But skin cancer can absolutely be deadly when it spreads beyond the skin, and certain types are far more dangerous than others. About 14,000 people in the United States are expected to die from skin cancer in 2025: roughly 8,430 from melanoma and another 5,680 from rarer non-melanoma types.
Whether skin cancer proves fatal depends almost entirely on two things: what type it is and how early it’s found.
The Three Main Types and Their Risks
Basal cell carcinoma is the most common skin cancer by a wide margin, and it’s almost never fatal. It grows slowly, rarely spreads to other parts of the body, and is typically cured with straightforward removal. It can cause significant local damage if ignored for years, eating into nearby tissue, but death from basal cell carcinoma is extremely uncommon.
Squamous cell carcinoma is the second most common type. It carries slightly more risk because it can occasionally spread, though this is still fairly rare. When squamous cell carcinoma does metastasize, the five-year survival rate drops below 50 percent. Most cases, however, are caught and removed long before that happens.
Melanoma is the type most people worry about, and for good reason. It accounts for the large majority of skin cancer deaths despite being less common than basal or squamous cell cancers. Melanoma is far more likely to spread to internal organs, and once it does, it becomes much harder to treat. There is also a rare type called Merkel cell carcinoma that is particularly aggressive. Its overall five-year survival rate is 69 percent, dropping to 31 percent when it has spread to distant organs.
Stage at Diagnosis Changes Everything
The single biggest factor determining whether skin cancer is fatal is how far it has progressed when a doctor finds it. For melanoma caught in its earliest stages (still confined to the skin), the five-year survival rate is 97.6 percent. That’s nearly the same as having no cancer at all. But melanoma that has already spread to distant organs has a five-year survival rate of just 16.2 percent. That gap, from 97.6 percent down to 16.2 percent, is one of the starkest in all of cancer medicine.
Tumor thickness plays a major role in this equation. Pathologists measure melanoma depth in millimeters, and this measurement is the single most important predictor of outcomes. Melanomas thinner than 1 millimeter are typically early-stage with excellent survival. Those thicker than 4 millimeters carry a substantially higher risk of spreading. This is why dermatologists treat even small suspicious spots seriously: a melanoma caught when it’s paper-thin is a different disease than one that has grown deep into the skin.
How Skin Cancer Becomes Fatal
Skin cancer doesn’t kill by damaging the skin itself. It kills when cancerous cells enter the bloodstream or lymphatic system and establish new tumors in vital organs. For melanoma, the most common sites of spread are the lungs, liver, bones, and brain.
Lung involvement is the leading cause of death in advanced melanoma, ultimately causing respiratory failure. The brain is the second most common cause of melanoma-related death. Melanoma has an unusual tendency to spread to the central nervous system, where it can cause bleeding and is especially difficult to treat because of the barrier that normally protects the brain from substances in the bloodstream. The liver is the most commonly affected internal organ overall.
Immunotherapy Has Changed the Outlook
Advanced melanoma used to be one of the most hopeless diagnoses in oncology. As recently as the early 2010s, patients with inoperable stage IV melanoma survived a median of about six months. That number has shifted dramatically. With modern immunotherapy, which works by helping the immune system recognize and attack cancer cells, median survival for advanced melanoma has improved to nearly six years.
The most effective approach combines two types of immune checkpoint therapy. Long-term follow-up data shows that patients receiving combination immunotherapy had a median overall survival of about 72 months (six years), compared to roughly 37 months with one type alone and 20 months with the other. These treatments don’t work for everyone, and side effects can be significant, but they’ve transformed stage IV melanoma from a near-certain death sentence into a condition where long-term survival is possible for a meaningful number of patients.
Who Faces the Highest Risk
Several factors push skin cancer risk toward a fatal outcome. Location matters: melanomas on the scalp, back, or other areas that are hard to self-examine tend to be found later, when they’re thicker and more dangerous. Men are more likely than women to die of melanoma, partly because they’re less likely to notice changes in their skin early and partly because melanomas in men more often appear on the trunk, where they’re less visible.
Older adults face higher mortality as well. The immune system weakens with age, making it harder to fight cancer that has begun to spread. People with suppressed immune systems, whether from medications or medical conditions, also face greater risk of aggressive skin cancer behavior.
The most actionable risk factor is delay. A mole that changes shape, color, or size, or a sore that won’t heal, is worth getting checked promptly. The difference between a thin melanoma and a thick one can be a matter of months, and that difference is often the difference between a minor procedure and a life-threatening illness.